Para Advisors’s AstraZeneca AZN Stock Holding History

Para Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-70,000	Closed	-$4.46M	–	17
2015 Q2	$4.46M	Buy	70,000 +45,000	+180%	+$3.08M	6.37%	6
2015 Q1	$1.71M	Hold	25,000	–	–	1.57%	15
2014 Q4	$1.76M	Hold	25,000	–	–	3.41%	11
2014 Q3	$1.79M	Sell	25,000 -50,000	-67%	-$3.66M	1.1%	26
2014 Q2	$5.57M	Buy	+75,000	New	+$5.42M	3.23%	9

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Para Advisors's AZN Position: Q3 2015 in Review

Para Advisors sold out of AstraZeneca (AZN) in Q3 2015, closing a stake of 70,000 shares — an estimated $4.46M sold.

Para Advisors first reported a position in AZN in Q2 2014 and held it in 5 quarters. The position peaked at $5.57M in Q2 2014. 371 funds tracked by Wall St. Rank hold AZN as of Q3 2015.

Para Advisors reported no remaining AstraZeneca position as of Q3 2015 after selling out during the quarter.
Para Advisors sold 70,000 AstraZeneca shares in Q3 2015, an estimated $4.46M.
Para Advisors first reported a position in AstraZeneca in Q2 2014 and held it in 5 quarters.
Para Advisors's AstraZeneca position peaked at $5.57M in Q2 2014.
371 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2015.

Based on Para Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.